Delving into the Latest Updates on Cisen Pharmaceutical Ltd. with Synapse

Overview

Tags

Infectious Diseases

Other Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	7
Endocrinology and Metabolic Disease	5
Neoplasms	4
Nervous System Diseases	3
Immune System Diseases	2
Hemic and Lymphatic Diseases	1

Top 5 Drug Type	Count

Small molecule drug	16

Top 5 Target	Count

PI3Ks x mTOR	2
APE1(DNA-(apurinic or apyrimidinic site) lyase)	1
influenza virus polymerase	1
CDK2 x CDK4 x CDK6	1
Ergosterol	1

[Translation] A single-center, open-label, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study to evaluate the bioequivalence of the test formulation, Ondansetron Hydrochloride Tablets (strength: 8 mg), and the reference formulation, Zofran® (strength: 8 mg), in healthy adult participants in the fasting and fed states.

主要研究目的：研究空腹和餐后状态下单次口服受试制剂盐酸昂丹司琼片（规格：8 mg，辰欣药业股份有限公司生产）与参比制剂盐酸昂丹司琼片（Zofran®，规格：8 mg，Novartis Pharma GmbH生产）在健康参与者体内的药代动力学，评价空腹和餐后状态口服两种制剂的生物等效性。次要研究目的：评估受试制剂盐酸昂丹司琼片（规格：8 mg）和参比制剂盐酸昂丹司琼片（Zofran®，规格：8 mg）在健康参与者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation ondansetron hydrochloride tablets (specification: 8 mg, produced by Chenxin Pharmaceutical Co., Ltd.) and the reference preparation ondansetron hydrochloride tablets (Zofran®, specification: 8 mg, produced by Novartis Pharma GmbH) in healthy participants after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation ondansetron hydrochloride tablets (specification: 8 mg) and the reference preparation ondansetron hydrochloride tablets (Zofran®, specification: 8 mg) in healthy participants.

Start Date14 Apr 2025

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

CTR20250836

/ Active, not recruitingNot Applicable

评估受试制剂丙泊酚中/长链脂肪乳注射液（规格：20 mL:0.2 g）与参比制剂丙泊酚中/长链脂肪乳注射液（规格：20 mL:0.2 g）在健康成年参与者空腹状态下的单中心、开放、随机、单剂量、两周期、两序列、交叉生物等效性试验

[Translation] A single-center, open, randomized, single-dose, two-period, two-sequence, crossover bioequivalence study to evaluate the test preparation of propofol medium/long chain fat emulsion injection (specification: 20 mL: 0.2 g) and the reference preparation of propofol medium/long chain fat emulsion injection (specification: 20 mL: 0.2 g) in healthy adult participants under fasting state

主要研究目的：研究空腹状态下单次静脉输注受试制剂丙泊酚中/长链脂肪乳注射液（规格：20 mL:0.2 g，辰欣药业股份有限公司生产）与参比制剂丙泊酚中/长链脂肪乳注射液（规格：20 mL:0.2 g，Fresenius Kabi Deutschland GmbH持证）在健康参与者体内的药代动力学参数，评价空腹状态下静脉输注两种制剂的生物等效性。次要研究目的：评估受试制剂丙泊酚中/长链脂肪乳注射液（规格：20 mL:0.2 g）和参比制剂丙泊酚中/长链脂肪乳注射液（规格：20 mL:0.2 g）在健康参与者中的安全性及探索两制剂在健康参与者中的药效。

[Translation]

The main purpose of the study is to study the pharmacokinetic parameters of a single intravenous infusion of the test preparation Propofol Medium/Long Chain Fat Emulsion Injection (Specification: 20 mL: 0.2 g, produced by Chenxin Pharmaceutical Co., Ltd.) and the reference preparation Propofol Medium/Long Chain Fat Emulsion Injection (Specification: 20 mL: 0.2 g, certified by Fresenius Kabi Deutschland GmbH) in healthy participants under fasting conditions, and to evaluate the bioequivalence of the two preparations by intravenous infusion under fasting conditions. Secondary purpose of the study is to evaluate the safety of the test preparation Propofol Medium/Long Chain Fat Emulsion Injection (Specification: 20 mL: 0.2 g) and the reference preparation Propofol Medium/Long Chain Fat Emulsion Injection (Specification: 20 mL: 0.2 g) in healthy participants and to explore the efficacy of the two preparations in healthy participants.

Start Date11 Apr 2025

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

CTR20250156

/ RecruitingNot Applicable

评估受试制剂艾普拉唑肠溶片与参比制剂在健康成年参与者空腹和餐后状态下的单中心、开放、随机、单剂量、四周期、两序列、完全重复交叉生物等效性研究

[Translation] A single-center, open-label, randomized, single-dose, four-period, two-sequence, fully repeated crossover bioequivalence study to evaluate the test formulation of ilaprazole enteric-coated tablets versus the reference formulation in healthy adult participants under fasting and fed conditions

主要研究目的：研究空腹和餐后状态下单次口服受试制剂艾普拉唑肠溶片（规格：5 mg，辰欣药业股份有限公司生产）与参比制剂艾普拉唑肠溶片（壹丽安®，规格：5 mg，丽珠集团丽珠制药厂生产）在健康参与者体内的药代动力学，评价空腹和餐后状态下口服两种制剂的生物等效性。次要研究目的：评估受试制剂艾普拉唑肠溶片（规格：5 mg）和参比制剂艾普拉唑肠溶片（壹丽安®，规格：5 mg）在健康参与者中的安全性。

[Translation]

The main purpose of the study is to study the pharmacokinetics of the test preparation ilaprazole enteric-coated tablets (specification: 5 mg, produced by Chenxin Pharmaceutical Co., Ltd.) and the reference preparation ilaprazole enteric-coated tablets (Yilian®, specification: 5 mg, produced by Livzon Pharmaceutical Factory of Livzon Group) in healthy participants after a single oral administration in the fasting and fed state, and to evaluate the bioequivalence of the two preparations after oral administration in the fasting and fed state. Secondary purpose of the study is to evaluate the safety of the test preparation ilaprazole enteric-coated tablets (specification: 5 mg) and the reference preparation ilaprazole enteric-coated tablets (Yilian®, specification: 5 mg) in healthy participants.

Start Date18 Feb 2025

Sponsor / Collaborator

Cisen Pharmaceutical Ltd.

100 Clinical Results associated with Cisen Pharmaceutical Ltd.

Login to view more data

0 Patents (Medical) associated with Cisen Pharmaceutical Ltd.

Login to view more data

1

Literatures (Medical) associated with Cisen Pharmaceutical Ltd.

Dangdai Huagong Yanjiiu

Analysis on Safety Characteristics and Fault Diagnosis Technology of Chemical Machinery and Equipment

Author: Li Ruoqing

Chem. machinery and equipment is the key to the development of chem. enterprises, and it affects the production value and efficiency of chem. enterprises.With the continuous innovation of technol., the safety of many chem. machinery and equipment has been significantly improved.Based on the safety characteristics and fault diagnosis anal. of Huangong machinery and equipment, this paper focuses on the influence of safety characteristics of chem. machinery and equipment, explores the principle of failure of chem. machinery and equipment and the diagnosis content of chem. equipment, and strives to optimize the management measures of chem. machinery and equipment and reduce the failure frequency of chem. machinery and equipment.

100 Deals associated with Cisen Pharmaceutical Ltd.

Login to view more data

100 Translational Medicine associated with Cisen Pharmaceutical Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 18 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

4

2

Phase 1 Clinical

Phase 2 Clinical

6

2

Phase 3 Clinical

Approved

2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Liranaftate ( Ergosterol )	-	Approved
Chondroitin Sulfate Sodium ( ELA2 )	Hyperlipidemias More	Approved
Sudapyridine ( ATP synthase )	Pulmonary Tuberculosis More	Phase 3
Fesoterodine Fumarate ( mAChRs )	Urinary Bladder, Overactive More	Phase 3
WXFL10030390 ( PI3Ks x mTOR )	Ovarian Cancer More	Phase 2